"J Med Econ"[Journal] - Search Results

Year	Number of Results
2007	1
2008	52
2009	44
2010	85
2011	123
2012	171
2013	174
2014	126
2015	154
2016	172
2017	200
2018	186
2019	200
2020	195
2021	161
2022	132
2023	182
2024	199
2025	209
2026	50

1

Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.

Yang M, Chai X, Ye D, Zhao A, Moradi A, Lotan Y. Yang M, et al. J Med Econ. 2026 Dec;29(1):672-687. doi: 10.1080/13696998.2026.2630599. Epub 2026 Mar 4. J Med Econ. 2026. PMID: 41780023 Free article.

2

Comparing deep learning and classical regression approaches for predicting healthcare expenditure and spending: a systematic review.

Lee JT, Yeh MH, Li VC, Chen HH, Liu YH, Chen YC, Wu DB. Lee JT, et al. J Med Econ. 2026 Dec;29(1):654-671. doi: 10.1080/13696998.2026.2630598. Epub 2026 Mar 4. J Med Econ. 2026. PMID: 41779998 Free article.

3

Clinical and methodological uncertainty in the economic evaluation of suzetrigine.

Alcántara Montero A. Alcántara Montero A. J Med Econ. 2026 Dec;29(1):638-640. doi: 10.1080/13696998.2026.2633944. Epub 2026 Mar 4. J Med Econ. 2026. PMID: 41779973 Free article. No abstract available.

4

Reply: clinical and methodological uncertainty in the economic evaluation of suzetrigine.

Garrison K, Ellis AG, Curtice TG, Rosen MM, Sussman M, Lee J, Lopez A. Garrison K, et al. J Med Econ. 2026 Dec;29(1):635-637. doi: 10.1080/13696998.2026.2633928. Epub 2026 Mar 4. J Med Econ. 2026. PMID: 41779957 Free article. No abstract available.

5

Management of moderate-to-highly exuding leg ulcers with polyacrylate superabsorbent wound dressings versus foam dressings in spanish settings: an early-stage cost-effectiveness and budget-impact analysis.

Veličković V, Torra I Bou JE, Cegri F, Llatas FP. Veličković V, et al. J Med Econ. 2026 Dec;29(1):712-725. doi: 10.1080/13696998.2026.2636435. Epub 2026 Mar 3. J Med Econ. 2026. PMID: 41776171 Free article.

6

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Kanumilli N, Osumili B, Evans J, Webb J, Buckingham M, Debackere N, Nowakowski P, Cattin J, Hunt B. Kanumilli N, et al. J Med Econ. 2026 Dec;29(1):698-711. doi: 10.1080/13696998.2026.2631920. Epub 2026 Mar 2. J Med Econ. 2026. PMID: 41771166 Free article.

7

Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study.

Hamel JI, Samnaliev M, Do L, Ito D, Pan Y, Dugar A, Novack A. Hamel JI, et al. J Med Econ. 2026 Dec;29(1):641-653. doi: 10.1080/13696998.2026.2633923. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41764034 Free article.

8

Enhanced patient outcomes and improved budget impact from increased PFO diagnostic testing in cryptogenic stroke workup: a US hospital perspective.

Volpi JJ, Tiozzo G, Neervoort J, Louwsma T, Marti AK, Landaas EJ, Nakum M, Imhoff RJ. Volpi JJ, et al. J Med Econ. 2026 Dec;29(1):620-634. doi: 10.1080/13696998.2026.2630603. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41764033 Free article.

9

Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation.

Forbes SP, Yay Donderici E, Zhang N, Raymond VM, Das AK, Liang PS. Forbes SP, et al. J Med Econ. 2026 Dec;29(1):609-619. doi: 10.1080/13696998.2026.2633027. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41764032 Free article.

10

Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States.

Fust K, Kohli M, Joshi K, Cartier S, Lee A, Van de Velde N, Weinstein M, Beck E. Fust K, et al. J Med Econ. 2026 Dec;29(1):574-593. doi: 10.1080/13696998.2026.2624967. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41764030 Free article.

11

Publisher's note.

[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):106. doi: 10.1080/13696998.2026.2635859. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41763986 Free article. No abstract available.

12

Breaking barriers in women's pelvic health: claims-based economic analysis and healthcare utilization of an AI care program compared to usual care.

Pereira AP, M Seet A, Domingues B, Janela D, Pradhan A, C Areias A, Tong X, Bento V, Yanamadala V, Cohen SP, Atherton J, Dias Correia F, Belz L, Costa F. Pereira AP, et al. J Med Econ. 2026 Dec;29(1):516-531. doi: 10.1080/13696998.2026.2627835. Epub 2026 Feb 24. J Med Econ. 2026. PMID: 41733548 Free article.

13

Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States.

Lopez A, Gargano M, Yang H, Ogunsile FJ, Li N, Xie Y, Jeyakumar S, Udeze C. Lopez A, et al. J Med Econ. 2026 Dec;29(1):547-562. doi: 10.1080/13696998.2026.2624971. Epub 2026 Feb 23. J Med Econ. 2026. PMID: 41730016 Free article.

14

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.

Qian F, Bensimon AG, Tzontcheva A, Benjamin K, Uppaluri R, Adkins D, Johnson G, Fernan C, Zheng D, Tang Y, Chafamo B, Muston D. Qian F, et al. J Med Econ. 2026 Dec;29(1):594-608. doi: 10.1080/13696998.2026.2633930. Epub 2026 Feb 23. J Med Econ. 2026. PMID: 41730003 Free article.

15

Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis.

Dong Y, Mao Z, Dominguez A, Park TJ. Dong Y, et al. J Med Econ. 2026 Dec;29(1):563-573. doi: 10.1080/13696998.2026.2630604. Epub 2026 Feb 22. J Med Econ. 2026. PMID: 41725292 Free article.

16

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany.

Subash R, Duan C, Hines DM, Zhang M, Kongnakorn T, Dworatzek E, Kisser A. Subash R, et al. J Med Econ. 2026 Dec;29(1):532-546. doi: 10.1080/13696998.2026.2628445. Epub 2026 Feb 22. J Med Econ. 2026. PMID: 41725198 Free article.

17

Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review.

Jovanoski N, Kaur G, Shukla H, Chana N, Kharawala S. Jovanoski N, et al. J Med Econ. 2026 Dec;29(1):433-454. doi: 10.1080/13696998.2026.2623789. Epub 2026 Feb 22. J Med Econ. 2026. PMID: 41723781 Free article. Review.

18

The healthcare resource utilization and costs associated with metabolic dysfunction-associated steatohepatitis among Medicare beneficiaries: a retrospective cohort study.

Albarmawi H, Tan A, Aly A, Hoovler A, Zhong C, Vaccaro J, Harton J, Mantry P. Albarmawi H, et al. J Med Econ. 2026 Dec;29(1):498-515. doi: 10.1080/13696998.2026.2630601. Epub 2026 Feb 20. J Med Econ. 2026. PMID: 41719199 Free article.

19

Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US.

Gouldson M, Le Q, Millen S, Racz J, Arrick B, Hartzfeld D, Heald B, Eymere S, De La O JP, Berdunov V, Cuyun Carter G. Gouldson M, et al. J Med Econ. 2026 Dec;29(1):467-480. doi: 10.1080/13696998.2026.2626242. Epub 2026 Feb 19. J Med Econ. 2026. PMID: 41711467 Free article.

20

Correction.

[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):431-432. doi: 10.1080/13696998.2026.2632462. Epub 2026 Feb 18. J Med Econ. 2026. PMID: 41708479 Free article. No abstract available.

21

Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population.

Fuji S, Ando H, Takaura K, Ishii K, Kawaguchi I, Alhasani S, Matsuyama F, Murata T, Liao L. Fuji S, et al. J Med Econ. 2026 Dec;29(1):455-466. doi: 10.1080/13696998.2026.2627829. Epub 2026 Feb 18. J Med Econ. 2026. PMID: 41705966 Free article.

22

Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.

Tan YZ, Breislin E, Woods M, Madin-Warburton M, Gladwell D, Zang A, Vadgama S, Doble B, Wiesinger A, Sola-Morales O. Tan YZ, et al. J Med Econ. 2026 Dec;29(1):481-497. doi: 10.1080/13696998.2026.2626239. Epub 2026 Feb 18. J Med Econ. 2026. PMID: 41705912 Free article.

23

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.

Simuzingili M, Favre-Bulle A, Mutschler T, Yi Z, Tsoumani E, Owusu-Edusei K. Simuzingili M, et al. J Med Econ. 2026 Dec;29(1):334-344. doi: 10.1080/13696998.2026.2622857. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41703735 Free article.

24

Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary.

Ladino D, Patterson K, Várnai M, Balogh É, Khurana V, Aguiar-Ibáñez R. Ladino D, et al. J Med Econ. 2026 Dec;29(1):379-392. doi: 10.1080/13696998.2026.2626240. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41703729 Free article.

25

The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review.

Cheung A, Manuel M, Mac S, Fakhraei R, Giangregorio A, Betschel SD. Cheung A, et al. J Med Econ. 2026 Dec;29(1):393-405. doi: 10.1080/13696998.2026.2628450. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41701183 Free article. Review.

26

Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data.

Porta C, Pradelli L, Cirotto G, Majorini MT, Garay OU, Calvaruso V, Fasano T, Napoli L, Foschi FG, Lampertico P. Porta C, et al. J Med Econ. 2026 Dec;29(1):406-420. doi: 10.1080/13696998.2026.2627833. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41701165 Free article.

27

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Dimopoulos MA, Boccadoro M, Einsele H, Rodriguez-Otero P, Hulin C, Perrot A, Leleu X, Caillot D, Facon T, Mina R, Gay F, Broijl A, Hajek R, Spencer A, Schjesvold F, Zweegman S, Nair S, Ammann E, He J, Nobrega M, Rowe M, Sitthi-Amorn A, Sonneveld P. Dimopoulos MA, et al. J Med Econ. 2026 Dec;29(1):421-430. doi: 10.1080/13696998.2026.2624972. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41701105 Free article. Clinical Trial.

28

Cost-effectiveness and budget impact of PFO closure: Cardioform vs Amplatzer and medical therapy for secondary stroke prevention in Australia.

Starmer G, Sharpe R, Wong A, ElMarkaby H, Louwsma T, Camuglia B, Fox D. Starmer G, et al. J Med Econ. 2026 Dec;29(1):363-379. doi: 10.1080/13696998.2026.2622856. Epub 2026 Feb 9. J Med Econ. 2026. PMID: 41661066 Free article.

29

Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access.

Aguiar-Ibáñez R, Goldschmidt D, Zhou ZY, Eales J, Peters S, Cardoso F, Ciani O, Arunachalam A, Haiderali A, Roediger A, Black CM, Martinez E, Garrison LP Jr. Aguiar-Ibáñez R, et al. J Med Econ. 2026 Dec;29(1):345-362. doi: 10.1080/13696998.2026.2623775. Epub 2026 Feb 7. J Med Econ. 2026. PMID: 41653456 Free article. Review.

30

Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspective.

Walter E, Ghinelli F, Goyer I, Leone M, Pirracchio R. Walter E, et al. J Med Econ. 2026 Dec;29(1):319-333. doi: 10.1080/13696998.2026.2622854. Epub 2026 Feb 4. J Med Econ. 2026. PMID: 41637478 Free article.

31

Economic burden of non-transfusion-dependent thalassemia in the United States.

Langer AL, Rane A, Gilroy KS, Zhao J, Lombard L, Lew CR, Sheth S. Langer AL, et al. J Med Econ. 2026 Dec;29(1):308-318. doi: 10.1080/13696998.2026.2618930. Epub 2026 Feb 3. J Med Econ. 2026. PMID: 41632448 Free article.

32

Assessing public economic gains from expanding HPV vaccination in Portugal: a governmental perspective analysis.

Kotsopoulos N, Connolly MP, Pavelyev A, Rodrigues B, Silva J, Sabale U. Kotsopoulos N, et al. J Med Econ. 2026 Dec;29(1):282-294. doi: 10.1080/13696998.2026.2617010. Epub 2026 Jan 29. J Med Econ. 2026. PMID: 41608993 Free article.

33

Cost implications of introducing the BIOFIRE FILMARRAY meningitis/encephalitis panel vs. real-time PCR in adult and pediatric populations in the UK.

Veljanoska E, Szende A, McGill F, Gomes S, Malik S. Veljanoska E, et al. J Med Econ. 2026 Dec;29(1):295-307. doi: 10.1080/13696998.2025.2609504. Epub 2026 Jan 29. J Med Econ. 2026. PMID: 41608961 Free article.

34

Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling study.

Burn O, Molloy K, Kanekiyo M, Parker C, Rothwell S, Pan JJ, Trueman D, Ritchie C. Burn O, et al. J Med Econ. 2026 Dec;29(1):250-262. doi: 10.1080/13696998.2025.2600875. Epub 2026 Jan 28. J Med Econ. 2026. PMID: 41603883 Free article.

35

Incorporating underreporting of epidemiological burden in COVID-19 models: a targeted literature review.

Chopra I, Yang J, Yehoshua A, Mendoza CF, Di Fusco M. Chopra I, et al. J Med Econ. 2026 Dec;29(1):193-212. doi: 10.1080/13696998.2026.2613591. Epub 2026 Jan 22. J Med Econ. 2026. PMID: 41569003 Free article. Review.

36

Calculating cost per event avoided using a composite number needed to treat.

Toliver J, Wang J, Bhavsar J, Sullivan SD. Toliver J, et al. J Med Econ. 2026 Dec;29(1):242-248. doi: 10.1080/13696998.2026.2615606. Epub 2026 Jan 21. J Med Econ. 2026. PMID: 41562647 Free article.

37

Correction.

[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):249. doi: 10.1080/13696998.2026.2618439. Epub 2026 Jan 21. J Med Econ. 2026. PMID: 41562633 Free article. No abstract available.

38

Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan.

Yang RA, Liu VT, Wu DB, Shen TK, Tan HH, Wang YH, Lee JT. Yang RA, et al. J Med Econ. 2026 Dec;29(1):227-241. doi: 10.1080/13696998.2026.2612867. Epub 2026 Jan 20. J Med Econ. 2026. PMID: 41556641 Free article.

39

Cost-effectiveness analysis of a 20-valent pneumococcal conjugate vaccine for pneumococcal disease prevention in the Slovak pediatric population.

Wannaadisai W, Nassar TP, Šebo P, Hroncova D, Kuchta L. Wannaadisai W, et al. J Med Econ. 2026 Dec;29(1):213-226. doi: 10.1080/13696998.2025.2610060. Epub 2026 Jan 19. J Med Econ. 2026. PMID: 41553236 Free article.

40

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.

Shadman M, Bouwmeester W, Mohseninejad L, Xu S, Jevdjevic M, Yang K, Williams R, Jansen JP. Shadman M, et al. J Med Econ. 2026 Dec;29(1):180-192. doi: 10.1080/13696998.2025.2609514. Epub 2026 Jan 19. J Med Econ. 2026. PMID: 41553230 Free article.

41

Cost-effectiveness of female-only and gender-neutral HPV vaccination strategies in Japan.

Kim M, Shim E. Kim M, et al. J Med Econ. 2026 Dec;29(1):155-168. doi: 10.1080/13696998.2025.2609508. Epub 2026 Jan 12. J Med Econ. 2026. PMID: 41524327 Free article.

42

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.

Gilis-Januszewska A, Bronikowska M, Binowski G, Jachimowicz M, Gueron B, Schmidt F, Kossi SD. Gilis-Januszewska A, et al. J Med Econ. 2026 Dec;29(1):135-154. doi: 10.1080/13696998.2025.2609506. Epub 2026 Jan 10. J Med Econ. 2026. PMID: 41518621 Free article.

43

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Than KS, Shafrin J, Muthukrishnan S, Paulose J, Bilano V, Kuypers N. Than KS, et al. J Med Econ. 2026 Dec;29(1):169-178. doi: 10.1080/13696998.2025.2606575. Epub 2026 Jan 10. J Med Econ. 2026. PMID: 41518611 Free article.

44

Clinical benefits and cost saving of achieving composite treatment targets for type 2 diabetes - A modeling study.

Si S, Wang R, Li J, Ding Y, Liu Y, Osumili B. Si S, et al. J Med Econ. 2026 Dec;29(1):107-117. doi: 10.1080/13696998.2025.2604454. Epub 2026 Jan 8. J Med Econ. 2026. PMID: 41504525 Free article.

45

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.

Lee HC, Yang C, Liu YH, Mu F, Wang J, Goble J, Patel N, Zhang X, Grajales-Cruz AF, Jiao T. Lee HC, et al. J Med Econ. 2026 Dec;29(1):93-105. doi: 10.1080/13696998.2025.2604457. Epub 2026 Jan 3. J Med Econ. 2026. PMID: 41483183 Free article.

46

A five-year cost-consequence analysis of extended-use etonogestrel implant versus other contraceptives.

Patel VP, Collins K, Heinemann K, Ngantung W, Saeedian M. Patel VP, et al. J Med Econ. 2026 Dec;29(1):66-76. doi: 10.1080/13696998.2025.2606600. Epub 2025 Dec 29. J Med Econ. 2026. PMID: 41460288 Free article.

47

Health-economic impact of implementing continuous vital sign monitoring in post-surgical patients in five European countries.

Syan J, Muench T, Fernández-Barceló C, Saunders R, Attebery J, Luchetti M, Erslon M, Beard J, Khan S. Syan J, et al. J Med Econ. 2026 Dec;29(1):50-65. doi: 10.1080/13696998.2025.2602364. Epub 2025 Dec 29. J Med Econ. 2026. PMID: 41460205 Free article.

48

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dranitsaris G, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK, Thompson SL, Teschemaker A, Shetty V, Narkhede M, Ermann D, Blau S. Dranitsaris G, et al. J Med Econ. 2026 Dec;29(1):30-40. doi: 10.1080/13696998.2025.2604971. Epub 2025 Dec 27. J Med Econ. 2026. PMID: 41454883 Free article.

49

Annual vaccination with BNT162b2 in Germany can avoid substantial clinical and economic burden of COVID-19 disease.

Barber A, Roiz J, Greenall S, Church E, Schmetz A, Riebel S, Yang J, Witzke O, Gandjour A. Barber A, et al. J Med Econ. 2026 Dec;29(1):16-28. doi: 10.1080/13696998.2025.2604970. Epub 2025 Dec 27. J Med Econ. 2026. PMID: 41454846 Free article.

50

Cost-effectiveness analysis of empagliflozin as an add-on to the standard of care for chronic kidney disease management in the Philippines.

Montilla PJ, Crisostomo AC, Cunanan E, de Lara-Valenzona MR, de Leon D, Encarnacion PJ, Estabillo AP, Gonzales CJ, Mallari-Catungal M, Perlas Tiongco Ii RH, Taneo MJ, Tan-Lim D, Togonon-Leaño JI, Yu D, Kimwell MJ, Villanueva AR. Montilla PJ, et al. J Med Econ. 2026 Dec;29(1):1-15. doi: 10.1080/13696998.2025.2602361. Epub 2025 Dec 24. J Med Econ. 2026. PMID: 41441751 Free article.

51

Population-level assessment of healthcare cost-effectiveness from the payer's perspective in the Czech Republic: methodology and threshold setting using administrative data.

Fojtíková M, Fiala J. Fojtíková M, et al. J Med Econ. 2025 Dec 24;29(1):263-281. doi: 10.1080/13696998.2025.2609503. Epub 2026 Jan 23. J Med Econ. 2025. PMID: 41572836 Free article.

52

A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer's disease.

Ressa R, Ettinger J, Chowdhury E, Graham L, Ndirangu K, Mancebo JZ, Bodnar C. Ressa R, et al. J Med Econ. 2025 Dec 24;29(1):118-134. doi: 10.1080/13696998.2025.2609499. Epub 2026 Jan 5. J Med Econ. 2025. PMID: 41488982 Free article. Review.

53

Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective.

Karim N, Waterhouse D, Jones S, Stollenwerk B. Karim N, et al. J Med Econ. 2025 Dec 18;29(1):77-92. doi: 10.1080/13696998.2025.2604968. Epub 2026 Jan 5. J Med Econ. 2025. PMID: 41488979 Free article.

54

Surgical aortic valve replacement with a novel bovine pericardial tissue valve: a real world comparison of short-term costs and outcomes in US hospitals.

Brown CR, Szeto WY, Dratch A, Murphy SME, Shanbhag A, Reifenberger M, Umaña JP. Brown CR, et al. J Med Econ. 2025 Dec 6;29(1):40-49. doi: 10.1080/13696998.2025.2597133. Epub 2026 Jan 5. J Med Econ. 2025. PMID: 41487071 Free article.

55

Body weight distribution of US patients with myasthenia gravis.

Tse K, Sato M, Menon RR, Yang H, Du M, Qi CZ. Tse K, et al. J Med Econ. 2025 Dec;28(1):2264-2271. doi: 10.1080/13696998.2025.2601460. Epub 2025 Dec 21. J Med Econ. 2025. PMID: 41422493 Free article.

56

The biologic paradox solved? The imminent arrival of omalizumab biosimilars in Europe.

Menzella F. Menzella F. J Med Econ. 2025 Dec;28(1):2258-2263. doi: 10.1080/13696998.2025.2601469. Epub 2025 Dec 19. J Med Econ. 2025. PMID: 41416998 Free article. No abstract available.

57

Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for pain.

Ballreich JM, Jeyakumar S, Garrison K, Lopez A, Cohen BG, Paffrath A, Steel P, Rubin JL. Ballreich JM, et al. J Med Econ. 2025 Dec;28(1):2247-2257. doi: 10.1080/13696998.2025.2602385. Epub 2025 Dec 18. J Med Econ. 2025. PMID: 41412118 Free article.

58

Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy.

Paoletti M, Marcellusi A, Di Laura D, van den Puttelaar R, van de Wetering G, Jootun M. Paoletti M, et al. J Med Econ. 2025 Dec;28(1):2236-2246. doi: 10.1080/13696998.2025.2601456. Epub 2025 Dec 17. J Med Econ. 2025. PMID: 41405268 Free article.

59

Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis.

Loftus TJ, Cho JY, Meraz M, Dhippayom T, Bock AM, Wagner CB, Thavorn K, Chaiyakunapruk N. Loftus TJ, et al. J Med Econ. 2025 Dec;28(1):2216-2235. doi: 10.1080/13696998.2025.2600217. Epub 2025 Dec 17. J Med Econ. 2025. PMID: 41405081 Free article.

60

Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population.

Lai Y, Greenall S, Taylor J, Neves C. Lai Y, et al. J Med Econ. 2025 Dec;28(1):2186-2197. doi: 10.1080/13696998.2025.2599670. Epub 2025 Dec 13. J Med Econ. 2025. PMID: 41389297 Free article.

61

Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir.

Fernandez MM, Brady BL, Evans KA, Sidhu GS, Cislo P, Ernst FR, Cappelleri JC, Chaudhary MA, Drabo EF, Mokgokong R. Fernandez MM, et al. J Med Econ. 2025 Dec;28(1):2198-2215. doi: 10.1080/13696998.2025.2601454. Epub 2025 Dec 13. J Med Econ. 2025. PMID: 41389193 Free article.

62

Budget impact of suzetrigine for the treatment of moderate-to-severe acute pain in Medicaid-insured adults.

Garrison K, Ellis AG, Curtice TG, Rosen MM, Sussman M, Lee J, Lopez A. Garrison K, et al. J Med Econ. 2025 Dec;28(1):2135-2149. doi: 10.1080/13696998.2025.2595884. Epub 2025 Dec 10. J Med Econ. 2025. PMID: 41369225 Free article.

63

Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States.

Gish RG, Mendler MH, Mena EA, Kim C, Murillo Perez CF, Pan Y, Samnaliev M, Ito D, Agapova M. Gish RG, et al. J Med Econ. 2025 Dec;28(1):2173-2185. doi: 10.1080/13696998.2025.2595885. Epub 2025 Dec 9. J Med Econ. 2025. PMID: 41363946 Free article.

64

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

Sammons S, Tarantino P, Gadi VK, Pathak P, Sopher G, Delea T, Stellato D. Sammons S, et al. J Med Econ. 2025 Dec;28(1):2150-2160. doi: 10.1080/13696998.2025.2594952. Epub 2025 Dec 8. J Med Econ. 2025. PMID: 41359414 Free article.

65

Value of germline BRCA testing in patients with breast cancer: critical review of cost-effectiveness analyses using published value frameworks.

Sun LA, Li Q, Tung A, Kang A, Kasle A, Chen Y, Xu X, Veenstra DL. Sun LA, et al. J Med Econ. 2025 Dec;28(1):2161-2172. doi: 10.1080/13696998.2025.2595887. Epub 2025 Dec 7. J Med Econ. 2025. PMID: 41353627 Free article. Review.

66

Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

Tarantino P, Sammons S, Gadi VK, Pathak P, Sopher G, Delea T, Stellato D. Tarantino P, et al. J Med Econ. 2025 Dec;28(1):2125-2134. doi: 10.1080/13696998.2025.2594951. Epub 2025 Dec 5. J Med Econ. 2025. PMID: 41347936 Free article.

67

Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin's impact on burden reduction.

Kim M, New E, Lim A, Lim J, Wee JY, Viswambaram A, Varghese L. Kim M, et al. J Med Econ. 2025 Dec;28(1):2103-2118. doi: 10.1080/13696998.2025.2590401. Epub 2025 Dec 2. J Med Econ. 2025. PMID: 41329235 Free article.

68

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder.

Masand PS, Clayton AH, Parikh M, Haile F, Germain G, Ripley S, Ma S, Laliberté F, Nabulsi N. Masand PS, et al. J Med Econ. 2025 Dec;28(1):2043-2056. doi: 10.1080/13696998.2025.2587412. Epub 2025 Nov 30. J Med Econ. 2025. PMID: 41320566 Free article.

69

Corneal cross-linking for keratoconus: a global economic and clinical perspective.

Gurnani B, Kaur K. Gurnani B, et al. J Med Econ. 2025 Dec;28(1):2119-2124. doi: 10.1080/13696998.2025.2587416. Epub 2025 Nov 30. J Med Econ. 2025. PMID: 41320236 Free article. No abstract available.

70

Effectiveness of the etonogestrel implant: an economic model of immediate postpartum use on pregnancy outcomes.

Patel VP, Collins K, Heinemann K, Ngantung W, Saeedian M. Patel VP, et al. J Med Econ. 2025 Dec;28(1):2091-2102. doi: 10.1080/13696998.2025.2593795. Epub 2025 Nov 27. J Med Econ. 2025. PMID: 41307487 Free article.

71

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Shafrin J, Jadhav K, Warren C, Quddus S, Zawadzki N, Yang D, Damon A, Spurrier K, Batt K, Wei D. Shafrin J, et al. J Med Econ. 2025 Dec;28(1):2082-2090. doi: 10.1080/13696998.2025.2593796. Epub 2025 Nov 26. J Med Econ. 2025. PMID: 41295925 Free article.

72

Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Wang S, Passos Chaves L, Olujohungbe O, Muthukrishnan S, Chaudhary A, Shafrin J. Wang S, et al. J Med Econ. 2025 Dec;28(1):2057-2070. doi: 10.1080/13696998.2025.2587415. Epub 2025 Nov 26. J Med Econ. 2025. PMID: 41295924 Free article.

73

Sex disparities of vaccine-preventable cancer mortality in Latin America.

Irene Parellada C, Siddiqui AH, Oliver E, Hughes R, Meiwald A, Orengo JC, Eiden A, Bencina G. Irene Parellada C, et al. J Med Econ. 2025 Dec;28(1):2071-2081. doi: 10.1080/13696998.2025.2587413. Epub 2025 Nov 26. J Med Econ. 2025. PMID: 41295897 Free article.

74

The price of progress: balancing short-term gains and long-term value in aortic valve replacement.

Layton G, Robayo V, Rathakrishnan B, Okoh A, Hirji S. Layton G, et al. J Med Econ. 2025 Dec;28(1):2039-2042. doi: 10.1080/13696998.2025.2590389. Epub 2025 Nov 22. J Med Econ. 2025. PMID: 41273707 Free article. No abstract available.

75

Real-world disease burden and health care resource utilization for patients with Barth syndrome.

Marjoram L, Huang Y, Koenig MK, Cohen BH, Anderson E. Marjoram L, et al. J Med Econ. 2025 Dec;28(1):2010-2026. doi: 10.1080/13696998.2025.2588729. Epub 2025 Nov 21. J Med Econ. 2025. PMID: 41268908 Free article.

76

A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population.

Flanigan J, Chaplin S, van Stiphout J, Schauf M, Tindal M, Gundlach A, Li E, Lyman GH. Flanigan J, et al. J Med Econ. 2025 Dec;28(1):2027-2038. doi: 10.1080/13696998.2025.2584885. Epub 2025 Nov 19. J Med Econ. 2025. PMID: 41258696 Free article.

77

Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): the influence of differing European health care payment systems on the potential financial impact of adoption.

Belsey J, Lapon J. Belsey J, et al. J Med Econ. 2025 Dec;28(1):1999-2009. doi: 10.1080/13696998.2025.2588728. Epub 2025 Nov 17. J Med Econ. 2025. PMID: 41247459 Free article.

78

Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy.

Reza N, Butzner M, Batra K, Amos Q, Buikema A, Shreay S, Owens A. Reza N, et al. J Med Econ. 2025 Dec;28(1):1979-1988. doi: 10.1080/13696998.2025.2584888. Epub 2025 Nov 16. J Med Econ. 2025. PMID: 41241831 Free PMC article.

79

The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model.

Kasle A, Li Q, Tung A, Xu X, Veenstra D. Kasle A, et al. J Med Econ. 2025 Dec;28(1):1968-1978. doi: 10.1080/13696998.2025.2583870. Epub 2025 Nov 10. J Med Econ. 2025. PMID: 41185933 Free article.

80

Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.

Jagannath S, Kharat A, Chinaeke E, Fu AZ, Perciavalle M, Huo S, Qureshi ZP. Jagannath S, et al. J Med Econ. 2025 Dec;28(1):1989-1998. doi: 10.1080/13696998.2025.2583668. Epub 2025 Nov 19. J Med Econ. 2025. PMID: 41178750 Free article.

81

Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact.

Szilcz M, Naghipour P, Fridh AC, Palmborg A, Toghanian S. Szilcz M, et al. J Med Econ. 2025 Dec;28(1):1955-1967. doi: 10.1080/13696998.2025.2580785. Epub 2025 Nov 10. J Med Econ. 2025. PMID: 41137859 Free article.

82

Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.

Mugwagwa T, Marcano Belisario J, Hartley L, Phan NTN. Mugwagwa T, et al. J Med Econ. 2025 Dec;28(1):1933-1954. doi: 10.1080/13696998.2025.2579407. Epub 2025 Nov 6. J Med Econ. 2025. PMID: 41134222 Free article.

83

Prostate cancer progression: a scoping review, pharmacoeconomic assessment, and evaluation of quality of life.

Dinis de Sousa R, Zagalo DM, Gouveia M, Gomes L, Santos Dias J, Mansinho A, Santos S, Mariano J, Canhão H, Rodrigues A. Dinis de Sousa R, et al. J Med Econ. 2025 Dec;28(1):1910-1932. doi: 10.1080/13696998.2025.2578100. Epub 2025 Oct 30. J Med Econ. 2025. PMID: 41128722 Free article.

84

Cost-utility analysis of an exclusive human milk diet for very low birthweight infants in Japan.

Igarashi A, Reyes SM, Mizuno K. Igarashi A, et al. J Med Econ. 2025 Dec;28(1):1899-1909. doi: 10.1080/13696998.2025.2578101. Epub 2025 Nov 1. J Med Econ. 2025. PMID: 41117636 Free article.

85

Toward an ethical future for orphan drugs: balancing access, affordability, and innovation.

Alum EU, Ekpang Ii JE, Ekpang PO, Ainebyoona C, Nwagu KE, Nwuruku OA, Muhammad K. Alum EU, et al. J Med Econ. 2025 Dec;28(1):1869-1886. doi: 10.1080/13696998.2025.2577514. Epub 2025 Oct 27. J Med Econ. 2025. PMID: 41117352 Free article. Review.

86

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Climente-Martí M, García-González X, Torres-Bondia FI, Lozano J, Gómez-Navarro V. Climente-Martí M, et al. J Med Econ. 2025 Dec;28(1):1857-1868. doi: 10.1080/13696998.2025.2575456. Epub 2025 Oct 25. J Med Econ. 2025. PMID: 41111438 Free article.

87

Development and validation of an agent-based cost-effectiveness model of varicella vaccination strategies in Australia.

Hodgkinson B, Scuffham P. Hodgkinson B, et al. J Med Econ. 2025 Dec;28(1):1840-1856. doi: 10.1080/13696998.2025.2577513. Epub 2025 Oct 24. J Med Econ. 2025. PMID: 41111311 Free article.

88

The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.

Ramos M, Larsen S, Fusco F, Lamotte M, Capehorn M. Ramos M, et al. J Med Econ. 2025 Dec;28(1):1887-1898. doi: 10.1080/13696998.2025.2575692. Epub 2025 Oct 28. J Med Econ. 2025. PMID: 41090945 Free article.

89

Cost-consequence analysis of three cardiac ablation technologies in paroxysmal atrial fibrillation.

Neužil P, Ferrero de Loma-Osorio A, Martínez Brotons Á, Bondanza Saavedra L, Mei DA, Moučka P, Uffenorde S, Vieira Ruiz J, Boriani G. Neužil P, et al. J Med Econ. 2025 Dec;28(1):1826-1839. doi: 10.1080/13696998.2025.2575460. Epub 2025 Oct 19. J Med Econ. 2025. PMID: 41090941 Free article.

90

Health state utilities associated with obstructive sleep apnea: preferences of patients with OSA and obesity in the UK and the US.

Stewart KD, Matza LS, Dunn JP, Neff LM, Niemeyer A, Boye KS, Shinde S. Stewart KD, et al. J Med Econ. 2025 Dec;28(1):1811-1825. doi: 10.1080/13696998.2025.2572051. Epub 2025 Oct 31. J Med Econ. 2025. PMID: 41089051 Free article.

91

Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): demonstration of savings from a societal perspective in the UK.

Chaudhuri KR, Bergmann L, Belsey J, Boodhna T, Leoncini E. Chaudhuri KR, et al. J Med Econ. 2025 Dec;28(1):1746-1760. doi: 10.1080/13696998.2025.2560759. Epub 2025 Oct 8. J Med Econ. 2025. PMID: 41054384 Free article.

92

Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.

Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R. Meng Y, et al. J Med Econ. 2025 Dec;28(1):1779-1797. doi: 10.1080/13696998.2025.2567190. Epub 2025 Oct 14. J Med Econ. 2025. PMID: 41039930 Free article.

93

A budget impact analysis of the Dario Diabetes Solution for type 2 diabetes mellitus in a US managed care population.

Wilson L, Martin C, Tripathi S, Dixit H, Miller J, Wang R, Lee WC. Wilson L, et al. J Med Econ. 2025 Dec;28(1):1721-1732. doi: 10.1080/13696998.2025.2564575. Epub 2025 Oct 6. J Med Econ. 2025. PMID: 41024731 Free article.

94

Frequency, duration, and cost of pulmonary exacerbations among patients with bronchiectasis.

Mohanty M, Leiras C, Sun H, Rau R, Fastenau J, Feliciano J, Devarajan SR. Mohanty M, et al. J Med Econ. 2025 Dec;28(1):1798-1810. doi: 10.1080/13696998.2025.2567761. Epub 2025 Oct 14. J Med Econ. 2025. PMID: 41017477 Free article.

95

Addendum.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):1682. doi: 10.1080/13696998.2025.2567759. Epub 2025 Sep 29. J Med Econ. 2025. PMID: 41017396 Free article. No abstract available.

96

The incremental net monetary benefit of higher-valent pneumococcal conjugate vaccines for adults: a systematic review and meta-analysis of economic evaluations.

Lee H, Cho JY, Vietri J, Dawson E, Chaiyakunapruk N. Lee H, et al. J Med Econ. 2025 Dec;28(1):1761-1778. doi: 10.1080/13696998.2025.2565902. Epub 2025 Oct 10. J Med Econ. 2025. PMID: 40994424 Free article.

97

Cost drivers and delays in recovery following rotator cuff repair: insights from a national claims database.

Pill S, Beckley SJ, Karim M, Stinton SK, Branch TP. Pill S, et al. J Med Econ. 2025 Dec;28(1):1709-1720. doi: 10.1080/13696998.2025.2563465. Epub 2025 Oct 1. J Med Econ. 2025. PMID: 40986644 Free article.

98

Economics of corneal cross-linking for keratoconus treatment.

Rapuano CJ, Lindstrom RL, Donnenfeld E, Berdahl JP, Thompson V, Kratochvil D, Carter J. Rapuano CJ, et al. J Med Econ. 2025 Dec;28(1):1696-1708. doi: 10.1080/13696998.2025.2564576. Epub 2025 Sep 29. J Med Econ. 2025. PMID: 40981503 Free article.

99

Cost-effectiveness analysis of universal hypothyroidism screening in the general population aged 30-65 years in Spain.

Zafón Llopis C, Vicente López O, Cruz Martos MÁ, de Los Santos Real H, Alcalá Revilla B, Ojeda Rife O, Pérez Troncoso D, Citoler Berdala B, Cucalón Arenal JM. Zafón Llopis C, et al. J Med Econ. 2025 Dec;28(1):1683-1695. doi: 10.1080/13696998.2025.2563973. Epub 2025 Sep 26. J Med Econ. 2025. PMID: 40971307 Free article.

100

Estimating the societal economic burden of food allergy in the United States.

Warren C, Whittington MD, Bilaver L, Kratochvil D, Liu R, Seetasith A, Ko S, Garmo V, Kowal S, Gupta S, Gupta R. Warren C, et al. J Med Econ. 2025 Dec;28(1):1669-1681. doi: 10.1080/13696998.2025.2563462. Epub 2025 Sep 25. J Med Econ. 2025. PMID: 40960448 Free article.

101

Evaluating the broad societal value of pembrolizumab in women's cancer in Brazil.

Wijenayake N, Ladino D, Patterson K, Rosim M, Rojas Rojas M, Davies A, Young K. Wijenayake N, et al. J Med Econ. 2025 Dec;28(1):1651-1668. doi: 10.1080/13696998.2025.2559532. Epub 2025 Sep 25. J Med Econ. 2025. PMID: 40959987 Free article.

102

Cost-utility analysis of icosapent ethyl in patients with high triglyceride levels and recent acute coronary syndrome in Catalonia.

Comin-Colet J, Freixa R, García-Muñoz N, Mallén-Alberdi M, Montaño J, Gaugris S, Mistry C, Tilley L, Vitale G, López S. Comin-Colet J, et al. J Med Econ. 2025 Dec;28(1):1574-1590. doi: 10.1080/13696998.2025.2557717. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40957613 Free article.

103

Correction.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):1573. doi: 10.1080/13696998.2025.2561429. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40957609 Free article. No abstract available.

104

Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular disease.

Ortiz N, Shehata J, Smart J, Leinwand B, Ali A, Katariya D, Dicklin MR, Hsieh A. Ortiz N, et al. J Med Econ. 2025 Dec;28(1):1616-1625. doi: 10.1080/13696998.2025.2558314. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40955449 Free article.

105

Navigating the economic value of treatment sequencing in large B-cell lymphoma: insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in Brazil.

Nabhan S, Kievit B, Blissett R, Ball G. Nabhan S, et al. J Med Econ. 2025 Dec;28(1):1550-1562. doi: 10.1080/13696998.2025.2554516. Epub 2025 Sep 17. J Med Econ. 2025. PMID: 40955441 Free article.

106

Budget impact of introducing an omalizumab biosimilar in 23 European countries.

Jang M, Lee J, Yi S, Kwon TS. Jang M, et al. J Med Econ. 2025 Dec;28(1):1639-1650. doi: 10.1080/13696998.2025.2558450. Epub 2025 Sep 18. J Med Econ. 2025. PMID: 40955168 Free article.

107

Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health plan.

Boller E, Raveendran S, Smith A, Noori W, Miner P, Kleintjens J. Boller E, et al. J Med Econ. 2025 Dec;28(1):1733-1745. doi: 10.1080/13696998.2025.2561472. Epub 2025 Oct 7. J Med Econ. 2025. PMID: 40944302 Free article.

108

Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.

Kardel P, Sheetz C, Maynard J, Sarocco P. Kardel P, et al. J Med Econ. 2025 Dec;28(1):1541-1550. doi: 10.1080/13696998.2025.2555141. Epub 2025 Sep 12. J Med Econ. 2025. PMID: 40938305 Free article.

109

Net present value cost analysis for treating retinitis pigmentosa.

Hellems S, Puri S, Yip S, Fehr J, Milentijevic D. Hellems S, et al. J Med Econ. 2025 Dec;28(1):1591-1601. doi: 10.1080/13696998.2025.2559533. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40923851 Free article.

110

Statement of Retraction: Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's Disease (aPD): demonstration of savings from a societal perspective in the UK.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):1500. doi: 10.1080/13696998.2025.2558292. Epub 2025 Sep 9. J Med Econ. 2025. PMID: 40923813 Free article. No abstract available.

111

Impact of drug utilization management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving DOACs in the US.

Subash R, Vodicka E, Deeba S, Salter C, Dickerson C, Stawowczyk E. Subash R, et al. J Med Econ. 2025 Dec;28(1):1602-1615. doi: 10.1080/13696998.2025.2558449. Epub 2025 Sep 18. J Med Econ. 2025. PMID: 40913582 Free article.

112

Assessment of healthcare resource utilization and direct medical cost in relation to treatment length of oral corticosteroids in biologic-initiated patients with ulcerative colitis: a Japanese claims database study.

Miyazaki C, Inoue T, Sugimoto S, Yoshigoe S, Li N. Miyazaki C, et al. J Med Econ. 2025 Dec;28(1):1526-1539. doi: 10.1080/13696998.2025.2555138. Epub 2025 Sep 13. J Med Econ. 2025. PMID: 40905194 Free article.

113

Real world evidence on health care resource utilization and economic burden of arrhythmias in patients with COPD.

Russo P, Nathan R, Poh J, Singh H, Wright B, Boyle K, Hendrickson E. Russo P, et al. J Med Econ. 2025 Dec;28(1):1564-1573. doi: 10.1080/13696998.2025.2555144. Epub 2025 Sep 11. J Med Econ. 2025. PMID: 40905164 Free article.

114

A retrospective cohort study of the economic burden of Pompe disease in patients treated with enzyme replacement therapy in the United States.

Steiner RD, Haselkorn T, Pillai NR, Young C, Solomon F, Xie B, Rozario N, Walzer M, Schoser B. Steiner RD, et al. J Med Econ. 2025 Dec;28(1):1626-1638. doi: 10.1080/13696998.2025.2556629. Epub 2025 Sep 24. J Med Econ. 2025. PMID: 40904046 Free article.

115

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Gordan LN, Fonseca G, Warner A, Alajrash A, Ming A, Tang D, Gavrilov S, Singh N, Heritage T, Griffin E, Swanson A, Slaff S. Gordan LN, et al. J Med Econ. 2025 Dec;28(1):1357-1369. doi: 10.1080/13696998.2025.2548739. Epub 2025 Sep 2. J Med Econ. 2025. PMID: 40891921 Free article.

116

The evolving burden of obesity in the US: a novel population-level system dynamics approach.

McEwan P, Faurby M, Lübker C, Padgett T, Toliver JC. McEwan P, et al. J Med Econ. 2025 Dec;28(1):1512-1525. doi: 10.1080/13696998.2025.2554518. Epub 2025 Sep 18. J Med Econ. 2025. Update in: J Med Econ. 2025 Dec;28(1):1682. doi: 10.1080/13696998.2025.2567759. PMID: 40880254 Free article. Updated.

117

Continuity of care for patients with chronic lymphocytic leukemia: an analysis of real-world data.

Gaballa S, Khanal M, Chen Y, Bhandari NR, Winfree KB, Abhyankar S, Hess LM. Gaballa S, et al. J Med Econ. 2025 Dec;28(1):1500-1511. doi: 10.1080/13696998.2025.2554514. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40880070 Free article.

118

Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States.

Hancock M, Beyer C, Fuchs M, Harisinghani M, Jalal P, Ndaa M, Samala N, Vargas JD, Jayaswal A. Hancock M, et al. J Med Econ. 2025 Dec;28(1):1370-1387. doi: 10.1080/13696998.2025.2550113. Epub 2025 Sep 2. J Med Econ. 2025. PMID: 40859753 Free article.

119

Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada.

Garcia DA, Mau G, Singh S, Spence M, Jensen MS, Goldenberg R. Garcia DA, et al. J Med Econ. 2025 Dec;28(1):1476-1499. doi: 10.1080/13696998.2025.2551449. Epub 2025 Sep 4. J Med Econ. 2025. PMID: 40853353 Free article.

120

Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury.

Humes HD, Kleinman N, Kammerer J, Iyer SPN, Goldstein SL, Kleinman A, Chung KK, Thakar CV. Humes HD, et al. J Med Econ. 2025 Dec;28(1):1467-1475. doi: 10.1080/13696998.2025.2550860. Epub 2025 Sep 4. J Med Econ. 2025. PMID: 40847756 Free article.

121

Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD.

Kluge B, Harris J, Sánchez-Collado I, Pérez-Román I, Paffett M, Christophel S, Harz C, Blankenburg M, Greenwood JP. Kluge B, et al. J Med Econ. 2025 Dec;28(1):1451-1466. doi: 10.1080/13696998.2025.2550331. Epub 2025 Sep 10. J Med Econ. 2025. PMID: 40838820 Free article.

122

Cost-effectiveness analysis of seasonal influenza vaccination compared to no vaccination in the United Arab Emirates and Iraq.

Al Dallal S, Ghazi S, Jabbar F, Farghaly M, Fasseeh AN, Korra N, Shalaby A, H Ahmed Y, Arraj M, Elgouhari S, Abdelsamie S, Fahim W, Hamandi Z, Tahoun M, Abaza S, Kovács G. Al Dallal S, et al. J Med Econ. 2025 Dec;28(1):1422-1439. doi: 10.1080/13696998.2025.2550115. Epub 2025 Sep 1. J Med Econ. 2025. PMID: 40838717 Free article.

123

Cost savings from prioritization of non-invasive modalities within CAD diagnostic protocols: a systematic review.

Kluge B, Harris J, Sánchez-Collado I, Pérez-Román I, Paffett M, Harz C, Christophel S, Blankenburg M, Greenwood JP. Kluge B, et al. J Med Econ. 2025 Dec;28(1):1388-1404. doi: 10.1080/13696998.2025.2549628. Epub 2025 Sep 1. J Med Econ. 2025. PMID: 40836913 Free article.

124

The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada.

Fust K, Kohli M, Cartier S, Joshi K, Van de Velde N, Beck E, Blake M. Fust K, et al. J Med Econ. 2025 Dec;28(1):1440-1450. doi: 10.1080/13696998.2025.2549630. Epub 2025 Sep 3. J Med Econ. 2025. PMID: 40827738 Free article.

125

Economic value of intra-articular knee OA therapies: a U.S. perspective.

Dasa V, Ngai W, Steele K, Preblick R, Watson H, Ong KL. Dasa V, et al. J Med Econ. 2025 Dec;28(1):1334-1347. doi: 10.1080/13696998.2025.2549629. Epub 2025 Aug 25. J Med Econ. 2025. PMID: 40827464 Free article.

126

Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder.

Awasthi S, Hadzi Boskovic D, Kapadia S. Awasthi S, et al. J Med Econ. 2025 Dec;28(1):1348-1356. doi: 10.1080/13696998.2025.2549653. Epub 2025 Aug 25. J Med Econ. 2025. PMID: 40827448 Free article.

127

Economic burden of growth hormone deficiency among adults who are at risk for and who have confirmed growth hormone deficiency using US real-world data.

Hoffman AR, Raveendran S, Manjelievskaia J, Komirenko AS, Winer I, Cheng J, Winer-Jones JP, Bonafede M, Miner P, Smith AR. Hoffman AR, et al. J Med Econ. 2025 Dec;28(1):1322-1333. doi: 10.1080/13696998.2025.2548741. Epub 2025 Aug 23. J Med Econ. 2025. PMID: 40826813 Free article.

128

Comparative analysis of all-cause health care resource utilization and costs among patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding in France: a nationwide cohort analysis.

Pesce G, Gusto G, Quignot N, Khachatryan A, Dai F, Sedjelmaci F, Chaves J, Subash R, Mokgokong R. Pesce G, et al. J Med Econ. 2025 Dec;28(1):1405-1421. doi: 10.1080/13696998.2025.2543214. Epub 2025 Sep 1. J Med Econ. 2025. PMID: 40761167 Free article.

129

Impact of systemic inflammation on healthcare resource utilization and cost in patients with atherosclerotic cardiovascular disease and chronic kidney disease.

Rudolfsen JH, Vukmirica J, Johansen P, Røder KL, Mortensen MB. Rudolfsen JH, et al. J Med Econ. 2025 Dec;28(1):1298-1306. doi: 10.1080/13696998.2025.2542024. Epub 2025 Aug 12. J Med Econ. 2025. PMID: 40758484 Free article.

130

Safety and efficacy of an intrinsic antitachycardia pacing algorithm in patients from Japan and South Korea: results from a cardiac device registry in the Asia Pacific region.

Goya M, Park SJ, Ando K, Holbrook R, Iskandar R, Jacobsen L, Mozingo JD, Joung B; SPARK Registry Investigators. Goya M, et al. J Med Econ. 2025 Dec;28(1):1307-1318. doi: 10.1080/13696998.2025.2543213. Epub 2025 Aug 13. J Med Econ. 2025. PMID: 40758483 Free article.

131

Economic impact of MAF testing for adjuvant bisphosphonate therapy in early breast cancer: a multi-regional budget impact analysis from a payer perspective.

Carapinha JL, Tercero JC, van den Berg R, Servitja S, Jean-Mairet J, Gomis RR, Carapinha R. Carapinha JL, et al. J Med Econ. 2025 Dec;28(1):1285-1297. doi: 10.1080/13696998.2025.2543212. Epub 2025 Aug 10. J Med Econ. 2025. PMID: 40751673 Free article.

132

A systematic review of health state utility values for influenza and influenza-like illness.

Heinrich R, Sende F, Thiesen J, Poshtiban A, Damm O, Alvarez FP, Schoenfelder T. Heinrich R, et al. J Med Econ. 2025 Dec;28(1):1252-1273. doi: 10.1080/13696998.2025.2542026. Epub 2025 Aug 6. J Med Econ. 2025. PMID: 40741673 Free article.

133

Comparison of enteral nutritional therapy to induce and maintain remission in paediatric patients with mild-to-moderate Crohn's disease: a cost-effectiveness analysis in the UK.

Patel M, Shergill-Bonner R, Sharma P, Capobianco ME, Steeds C. Patel M, et al. J Med Econ. 2025 Dec;28(1):1214-1225. doi: 10.1080/13696998.2025.2539644. Epub 2025 Aug 1. J Med Econ. 2025. PMID: 40734531 Free article.

134

Cost-effectiveness analysis of first-line treatment for advanced soft tissue sarcomas in China.

Zhang J, Liang Y, Guan X, Zhao X, Liu Y, Xu R, Li H, Guo C. Zhang J, et al. J Med Econ. 2025 Dec;28(1):1274-1284. doi: 10.1080/13696998.2025.2539642. Epub 2025 Aug 8. J Med Econ. 2025. PMID: 40711764 Free article.

135

Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.

Schmalhofer C, Otte Im Kampe E, Eheberg D, Sandhu H, Maier M, Perschke A, Mugwagwa T, Fröling E, Kisser A. Schmalhofer C, et al. J Med Econ. 2025 Dec;28(1):1226-1240. doi: 10.1080/13696998.2025.2536974. Epub 2025 Jul 31. J Med Econ. 2025. PMID: 40709376 Free article.

136

One man's waste is another man's treasure: the case of wastewater-based Respiratory Syncytial Virus surveillance's efficiency.

Petrou P, Petrou C. Petrou P, et al. J Med Econ. 2025 Dec;28(1):1319-1321. doi: 10.1080/13696998.2025.2539641. Epub 2025 Aug 12. J Med Econ. 2025. PMID: 40708535 Free article. No abstract available.

137

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland.

Ambresin A, Quist SW, Boer M, Maamari S, Barthelmes D. Ambresin A, et al. J Med Econ. 2025 Dec;28(1):1198-1213. doi: 10.1080/13696998.2025.2536420. Epub 2025 Jul 29. J Med Econ. 2025. PMID: 40692491 Free article.

138

Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland.

Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M. Wislez M, et al. J Med Econ. 2025 Dec;28(1):1151-1167. doi: 10.1080/13696998.2025.2535225. Epub 2025 Jul 23. J Med Econ. 2025. PMID: 40685969 Free article.

139

Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany.

Perdrizet J, Schröder D, Kühne F, Schiffner-Rohe J, Laurenz M, Theilacker C, Ilic A, Ta A, von Eiff C. Perdrizet J, et al. J Med Econ. 2025 Dec;28(1):1191-1197. doi: 10.1080/13696998.2025.2536430. Epub 2025 Jul 25. J Med Econ. 2025. PMID: 40685944 Free article.

140

Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor-based antiretroviral regimens.

Chuo CY, Christoph MJ, Zachry W, de Boer M, Chen M, Trom C. Chuo CY, et al. J Med Econ. 2025 Dec;28(1):1241-1251. doi: 10.1080/13696998.2025.2536422. Epub 2025 Aug 4. J Med Econ. 2025. PMID: 40677000 Free article.

141

Budget impact analysis of Haemate-P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Wilson MR, Mendez P, McDade CL, Vidal Barrientos L, Megías-Vericat JE, Escolar G, Karampampa K, Panebianco M, Yan S. Wilson MR, et al. J Med Econ. 2025 Dec;28(1):1183-1190. doi: 10.1080/13696998.2025.2535232. Epub 2025 Jul 24. J Med Econ. 2025. PMID: 40676998 Free article.

142

The NOPAIN Act: providing access and reimbursement for qualified non-opioid options for Medicare patients with potential implications for other patient populations.

Bour ES. Bour ES. J Med Econ. 2025 Dec;28(1):1132-1136. doi: 10.1080/13696998.2025.2530863. Epub 2025 Jul 20. J Med Econ. 2025. PMID: 40667697 Free article. No abstract available.

143

Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States.

Volpi JJ, Kasner SE, Looman T, Tiozzo G, Louwsma T, Imhoff RJ, Landaas EJ. Volpi JJ, et al. J Med Econ. 2025 Dec;28(1):1137-1150. doi: 10.1080/13696998.2025.2535236. Epub 2025 Jul 22. J Med Econ. 2025. PMID: 40665656 Free article.

144

Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).

Bilen MA, Lowentritt B, Burbage S, Kinkead F, Khilfeh I, Rossi C, Du S, Wong G, Pilon D, Joshi K, Shore ND. Bilen MA, et al. J Med Econ. 2025 Dec;28(1):1096-1109. doi: 10.1080/13696998.2025.2530865. Epub 2025 Jul 16. J Med Econ. 2025. PMID: 40660892 Free article.

145

Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis.

Kotsopoulos N, Connolly MP, Nur S, Daniels V, Pavelyev A, Sabale U, Favre-Bulle A. Kotsopoulos N, et al. J Med Econ. 2025 Dec;28(1):1168-1182. doi: 10.1080/13696998.2025.2532458. Epub 2025 Jul 24. J Med Econ. 2025. PMID: 40657816 Free article.

146

Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada.

Nguyen S, Wehler E, Langevin C, Bensimon A, Leighl NB, Sarkar S, Hu X, Xu R, Lang BM, Vohra D, Arunachalam A, Insinga RP. Nguyen S, et al. J Med Econ. 2025 Dec;28(1):1110-1131. doi: 10.1080/13696998.2025.2530862. Epub 2025 Jul 21. J Med Econ. 2025. PMID: 40654114 Free article.

147

Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a review.

Dong OM, Manga N, Zhong Y, Zhang Y, Krause T, Hancock H, Brockbank J, Griffin J, Herring WL, Wolowacz S. Dong OM, et al. J Med Econ. 2025 Dec;28(1):1045-1060. doi: 10.1080/13696998.2025.2522010. Epub 2025 Jul 15. J Med Econ. 2025. PMID: 40635626 Free article. Review.

148

Economic impact of a digital tobacco cessation program: healthcare savings and productivity gains in a self-insured manufacturing company.

Brault M, Rein DB, Graham AL. Brault M, et al. J Med Econ. 2025 Dec;28(1):1061-1074. doi: 10.1080/13696998.2025.2529721. Epub 2025 Jul 10. J Med Econ. 2025. PMID: 40619901 Free article.

149

Cost-benefit analysis of a quadrivalent influenza vaccine in India.

Vora A, Tiwaskar M, Pai HD, Jones A, Kim K, Kim H. Vora A, et al. J Med Econ. 2025 Dec;28(1):1086-1095. doi: 10.1080/13696998.2025.2529722. Epub 2025 Jul 15. J Med Econ. 2025. PMID: 40611765 Free article.

150

Productivity loss associated with premature mortality due to human papillomavirus-related cancers in Poland.

Jaworski R, Czech M, Wójcik A, Sabale U, Pinkas J. Jaworski R, et al. J Med Econ. 2025 Dec;28(1):1014-1022. doi: 10.1080/13696998.2025.2523161. Epub 2025 Jul 3. J Med Econ. 2025. PMID: 40607842 Free article.

151

Delay in receiving lab test results increases the costs of treating an episode of care for treating urinary tract infections.

Thorpe KE, Joski PJ. Thorpe KE, et al. J Med Econ. 2025 Dec;28(1):1037-1044. doi: 10.1080/13696998.2025.2527509. Epub 2025 Jul 10. J Med Econ. 2025. PMID: 40586645 Free article.

152

Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy.

Maas L, Contreras-Meca C, Ghezzo S, Belmans F, Corsi A, Cant J, Vos W, Bobowicz M, Rygusik M, Laski DK, Annemans L, Hiligsmann M; EuCanImage Working Group; *EuCanImage Working Group. Maas L, et al. J Med Econ. 2025 Dec;28(1):1023-1036. doi: 10.1080/13696998.2025.2525006. Epub 2025 Jul 11. J Med Econ. 2025. PMID: 40586549 Free PMC article.

153

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).

Michalak W, Zhao Z, Faurby M, Alvarez S, Fitch A. Michalak W, et al. J Med Econ. 2025 Dec;28(1):1075-1085. doi: 10.1080/13696998.2025.2526282. Epub 2025 Jul 12. J Med Econ. 2025. PMID: 40579810 Free article.

154

Quantifying all-cause healthcare resource utilization and costs of children with mild-to-moderate long COVID in France.

Yang J, Tamberou C, Arnee E, Squara PA, Boukhlal A, Nguyen JL, Volkman HR, Fievez S, Lepoutre-Bourguet M, Ben Romdhane H, Renaudat C, Crépey P, Robineau O. Yang J, et al. J Med Econ. 2025 Dec;28(1):1002-1013. doi: 10.1080/13696998.2025.2525002. Epub 2025 Jul 3. J Med Econ. 2025. PMID: 40574623 Free article.

155

Selection bias in active-control trials: implications for HTAs and recommendations.

Francois C. Francois C. J Med Econ. 2025 Dec;28(1):987-989. doi: 10.1080/13696998.2025.2523669. Epub 2025 Jun 26. J Med Econ. 2025. PMID: 40569154 Free article. No abstract available.

156

Addendum.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):986. doi: 10.1080/13696998.2025.2524268. Epub 2025 Jun 24. J Med Econ. 2025. PMID: 40552931 Free article. No abstract available.

157

Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective.

Moraes Dos Santos F, Rodríguez Martínez C, Giovini V, Espinoza MA, Balmaceda C, Romero J. Moraes Dos Santos F, et al. J Med Econ. 2025 Dec;28(1):964-973. doi: 10.1080/13696998.2025.2520701. Epub 2025 Jun 20. J Med Econ. 2025. PMID: 40528625 Free article.

158

Public health impact and cost-effectiveness of implementing gender-neutral vaccination with a 9-valent HPV vaccine in Japan: a modeling study.

Palmer C, Matsuki T, Tobe K, You X, Chen YT. Palmer C, et al. J Med Econ. 2025 Dec;28(1):974-985. doi: 10.1080/13696998.2025.2520703. Epub 2025 Jun 20. J Med Econ. 2025. PMID: 40528568 Free article.

159

Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective.

Vonck K, Bodart O, Weckhuysen S, Tanghe A, Callebaut B, Verdonck C, Van den Bergh L, Legros B. Vonck K, et al. J Med Econ. 2025 Dec;28(1):990-1001. doi: 10.1080/13696998.2025.2520182. Epub 2025 Jun 27. J Med Econ. 2025. PMID: 40526429 Free article.

160

Correction.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):921. doi: 10.1080/13696998.2025.2520692. Epub 2025 Jun 13. J Med Econ. 2025. PMID: 40512608 Free article. No abstract available.

161

A claims-based current clinical course of the post-treatment period after a unilateral elbow fracture.

Molina FP, Karim M, Beckley SJ, Stinton SK, Branch TP. Molina FP, et al. J Med Econ. 2025 Dec;28(1):934-943. doi: 10.1080/13696998.2025.2517499. Epub 2025 Jun 19. J Med Econ. 2025. PMID: 40501285 Free article.

162

Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting.

Nilsson K, Fridhammar A, Ota R, Sall Jensen M, Willis M, Persson S. Nilsson K, et al. J Med Econ. 2025 Dec;28(1):944-963. doi: 10.1080/13696998.2025.2517506. Epub 2025 Jun 22. J Med Econ. 2025. PMID: 40501229 Free article.

163

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.

Gordan LN, Bensimon AG, Mu F, Kim N, Wu B, Lin D, Paner A, Fowler J, Marshall A, Van Sanden S, Ammann E, Goble J, Zhang X, Le HH, Min EE, Garrison LP Jr. Gordan LN, et al. J Med Econ. 2025 Dec;28(1):910-920. doi: 10.1080/13696998.2025.2514909. Epub 2025 Jun 14. J Med Econ. 2025. PMID: 40495704 Free article.

164

Economic impact of in-office pediatric tympanostomy tube placement using a tympanostomy tube delivery device in a commercially- and Medicaid-insured US population.

Moynihan M, Ross R, Delgado J, Gerber M, Liu G. Moynihan M, et al. J Med Econ. 2025 Dec;28(1):899-909. doi: 10.1080/13696998.2025.2514925. Epub 2025 Jun 10. J Med Econ. 2025. PMID: 40478175 Free article.

165

Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France.

Guilmet C, Lesage H, Cotté FE, Moreau R, Marant Micallef C, Née M, Guitard-Dehoux D, Belhassen M, Danchin N. Guilmet C, et al. J Med Econ. 2025 Dec;28(1):859-870. doi: 10.1080/13696998.2025.2514381. Epub 2025 Jun 6. J Med Econ. 2025. Update in: J Med Econ. 2025 Dec;28(1):986. doi: 10.1080/13696998.2025.2524268. PMID: 40476700 Free article. Updated.

166

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan.

van de Wetering G, Kim H, Roberts D, Hikichi Y, Smith M, Tada Y. van de Wetering G, et al. J Med Econ. 2025 Dec;28(1):922-933. doi: 10.1080/13696998.2025.2515771. Epub 2025 Jun 17. J Med Econ. 2025. PMID: 40468645 Free article.

167

Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States.

McIntyre RS, Parikh M, Ta J, Waraich S, Cohen-Stavi C, Marci C, Nabulsi N. McIntyre RS, et al. J Med Econ. 2025 Dec;28(1):885-898. doi: 10.1080/13696998.2025.2513766. Epub 2025 Jun 10. J Med Econ. 2025. PMID: 40445745 Free article.

168

Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries.

Pal S, Beins M, Dobson A, Kim S, Kim S, Heath S, Zirath R. Pal S, et al. J Med Econ. 2025 Dec;28(1):848-858. doi: 10.1080/13696998.2025.2510814. Epub 2025 Jun 4. J Med Econ. 2025. PMID: 40434805 Free article.

169

Development and validation of an advanced data analytics model to support strategic point-of-care testing utilization decisions in the emergency department.

Leon-Justel A, Jimenez-Barragan M, Navarro-Bustos C, Martin-Perez S, Garrido-Castilla JM, Morales-Barroso IM, Oltra-Hostalet F, Fernandez-Gallardo MF, Diaz-Luque A, Eugenio-Pizarro A, Luque-Cid A, Sanchez-Mora C. Leon-Justel A, et al. J Med Econ. 2025 Dec;28(1):871-884. doi: 10.1080/13696998.2025.2508659. Epub 2025 Jun 7. J Med Econ. 2025. PMID: 40434437 Free article.

170

Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia.

Urrego-Reyes J, Marrugo Arnedo C, Jaramillo H, Realpe OE, Rojas MM, Patel A, Black C, Borse R. Urrego-Reyes J, et al. J Med Econ. 2025 Dec;28(1):823-834. doi: 10.1080/13696998.2025.2510807. Epub 2025 May 31. J Med Econ. 2025. PMID: 40417835 Free article. Clinical Trial.

171

Cost-utility analysis of difelikefalin for the treatment of moderate to severe Chronic Kidney Disease associated-Pruritus (CKD-aP) in adult patients receiving haemodialysis in Spain.

Sánchez-Alvarez E, Poveda JL, Sánchez-Villanueva R, De La Paz Cañizares I, Ramirez de Arellano A, Ruiz-Andrés O. Sánchez-Alvarez E, et al. J Med Econ. 2025 Dec;28(1):835-847. doi: 10.1080/13696998.2025.2501874. Epub 2025 Jun 4. J Med Econ. 2025. PMID: 40411773 Free article.

172

Economic option value associated with surgical aortic valve replacement using a novel bioprosthetic and a future transcatheter aortic valve-in-valve procedure.

Keuffel EL, Reifenberger M, Pellegrini A, Yadav P, Thourani VH. Keuffel EL, et al. J Med Econ. 2025 Dec;28(1):778-787. doi: 10.1080/13696998.2025.2503664. Epub 2025 May 22. J Med Econ. 2025. PMID: 40401761 Free article.

173

Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.

Aprikian A, Saad F, Wywial E, McLean T, Johnston K, Li Y, Chilelli A. Aprikian A, et al. J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23. J Med Econ. 2025. PMID: 40395149 Free article.

174

Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs.

Petitjean A, Shang H, Bullement A, Latimer N. Petitjean A, et al. J Med Econ. 2025 Dec;28(1):803-813. doi: 10.1080/13696998.2025.2506968. Epub 2025 May 24. J Med Econ. 2025. PMID: 40391406 Free article.

175

Cost-of-illness of heart failure with preserved and reduced ejection fraction in the Philippines.

Añonuevo J, Aquino CO, Cunanan E, Encarnacion PJ, Llanes EJ, Orolfo DD, Permejo C, Salvador D Jr, Taneo MJ, Villanueva AR, Ong-Garcia H, Montilla PJ. Añonuevo J, et al. J Med Econ. 2025 Dec;28(1):814-822. doi: 10.1080/13696998.2025.2504269. Epub 2025 May 31. J Med Econ. 2025. PMID: 40380760 Free article.

176

A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop.

Al-Omar HA, Almuhsin AA, Almudaiyan LH, Al-Najjar AH, Abu Esba LC, Almodaimegh H, Altawil ES, Yousef CC, Khan MA, AlYahya K, Alamre J, Maraiki F, Espín J, Tarricone R, Kanavos P. Al-Omar HA, et al. J Med Econ. 2025 Dec;28(1):753-765. doi: 10.1080/13696998.2025.2506967. Epub 2025 May 21. J Med Econ. 2025. PMID: 40371839 Free article.

177

Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia.

Kota V, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Guérin A, Jadhav K. Kota V, et al. J Med Econ. 2025 Dec;28(1):743-752. doi: 10.1080/13696998.2025.2506265. Epub 2025 May 21. J Med Econ. 2025. PMID: 40357629 Free article.

178

Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective.

Gulati A, Mittal N, Kane S, Creveling T, Bires N, Fisher DA, Chanan N, Koushik AK, Upadhyay N. Gulati A, et al. J Med Econ. 2025 Dec;28(1):709-718. doi: 10.1080/13696998.2025.2503661. Epub 2025 May 15. J Med Econ. 2025. PMID: 40351121 Free article.

179

The benefits of telehealth in promoting equity in blood cancer care - results of a multi-stakeholder forum and systematic literature review.

Mikhael J, Darlington D, Howell B, Hydren J, Hernandez T, Werner S, Iraca T, Arnett M, Gonzalez V, Peschin S, Balch AJ, Moran D, Young-Daniels R, Banjo O, Obeng GD, Asiedu-Ayeh B, Kawuo S, Tukur AM, Mohammed I, Obeng AP, Csanádi M, Lew T, Choon-Quinones M. Mikhael J, et al. J Med Econ. 2025 Dec;28(1):788-802. doi: 10.1080/13696998.2024.2438561. Epub 2025 May 27. J Med Econ. 2025. PMID: 40340653 Free article.

180

Unpacking the post-COVID association between unexpected births and excess deaths.

Coleman L. Coleman L. J Med Econ. 2025 Dec;28(1):726-733. doi: 10.1080/13696998.2025.2500825. Epub 2025 May 16. J Med Econ. 2025. PMID: 40336191 Free article.

181

Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study.

Ball BJ, Song R, Zanardo E, Huynh L, Mohan M, Pinaire M, Tang D, Yenikomshian M, Swanson A, Gavrilov S, Slaff S. Ball BJ, et al. J Med Econ. 2025 Dec;28(1):719-725. doi: 10.1080/13696998.2025.2498852. Epub 2025 May 21. J Med Econ. 2025. PMID: 40329816 Free article.

182

Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.

Kuruvilla J, Sehn LH, Whitney S, Patel AR, Cameron H, Reid GGJ. Kuruvilla J, et al. J Med Econ. 2025 Dec;28(1):688-695. doi: 10.1080/13696998.2025.2498853. Epub 2025 May 9. J Med Econ. 2025. PMID: 40314691 Free article.

183

The patient journey and burden of disease in Demodex blepharitis in the United States.

Periman LM, Whitley WO, Maiti S, Mun J, Ho AN, Oak B, Athavale A, Yeu E. Periman LM, et al. J Med Econ. 2025 Dec;28(1):734-742. doi: 10.1080/13696998.2025.2500224. Epub 2025 May 21. J Med Econ. 2025. PMID: 40314599 Free article.

184

Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric national immunization program.

Preda A, Ta A, Vinand E, Purdel V, Zdrafcovici AM, Ilic A, Perdrizet J. Preda A, et al. J Med Econ. 2025 Dec;28(1):696-708. doi: 10.1080/13696998.2025.2499333. Epub 2025 May 14. J Med Econ. 2025. PMID: 40304629 Free article.

185

Economic evaluation of PCV21 in vaccine-naïve adults aged 19-64 years with underlying medical conditions in the United States.

Yi Z, Elbasha EH, Owusu-Edusei K. Yi Z, et al. J Med Econ. 2025 Dec;28(1):665-673. doi: 10.1080/13696998.2025.2496070. Epub 2025 May 10. J Med Econ. 2025. PMID: 40270275 Free article.

186

Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer.

Bekaii-Saab T, Cho SK, Hocum B, Grossman J, Appukkuttan S, Babajanyan S, Marian M, Lee W, Barzi A, Yang M. Bekaii-Saab T, et al. J Med Econ. 2025 Dec;28(1):655-663. doi: 10.1080/13696998.2025.2496068. Epub 2025 Apr 28. J Med Econ. 2025. PMID: 40265856 Free article.

187

Correction.

[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):606. doi: 10.1080/13696998.2025.2494951. Epub 2025 Apr 21. J Med Econ. 2025. PMID: 40259608 Free article. No abstract available.

188

An Italian cost-utility analysis of 20-valent pneumococcal conjugate vaccine for routine vaccination in infants.

Basile M, Rumi F, Fortunato A, Antonini D, Di Virgilio R, Novelli G, Pagliaro A, Di Brino E. Basile M, et al. J Med Econ. 2025 Dec;28(1):674-687. doi: 10.1080/13696998.2025.2495461. Epub 2025 May 15. J Med Econ. 2025. PMID: 40257854 Free article.

189

Optimizing scan times in clinical neuroimaging: the potential of synthetic MRI.

von Hessling A, Stahl F, Kellner-Weldon F. von Hessling A, et al. J Med Econ. 2025 Dec;28(1):649-655. doi: 10.1080/13696998.2025.2496065. Epub 2025 Apr 28. J Med Econ. 2025. PMID: 40257425 Free article.

190

Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States.

White B, Harris M, Villacorta R, Sun A, Milev S, Lucherini S. White B, et al. J Med Econ. 2025 Dec;28(1):625-637. doi: 10.1080/13696998.2025.2494943. Epub 2025 Apr 25. J Med Econ. 2025. PMID: 40253592 Free article.

191

U.S. payer budget impact of the Leva Pelvic Health System to improve pelvic floor muscle training as first-line treatment of female urinary incontinence compare to real-world clinical practice.

Hall E, Sharma A, Goss TF, Hung K. Hall E, et al. J Med Econ. 2025 Dec;28(1):637-647. doi: 10.1080/13696998.2025.2494940. Epub 2025 May 5. J Med Econ. 2025. PMID: 40249373 Free article.

192

The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice.

Gnesi M, Daniel F, Mongelli V, Merlo A, Cosentino N, Maurizi AR, Nugnes M, Leogrande M, Degli Esposti L. Gnesi M, et al. J Med Econ. 2025 Dec;28(1):576-585. doi: 10.1080/13696998.2025.2487357. Epub 2025 Apr 17. J Med Econ. 2025. PMID: 40244700 Free article.

193

Analyzing factors influencing hospitalization costs for five common cancers in China using neural network models.

Jiang H, Ren S, Zhang S, Luo X, He R, Wang SF, Yan JD, Zhou S, Yin C, Xiao Y, Li Z. Jiang H, et al. J Med Econ. 2025 Dec;28(1):615-624. doi: 10.1080/13696998.2025.2494459. Epub 2025 Apr 24. J Med Econ. 2025. PMID: 40241623 Free article.

194

The multiple criteria qualitative value-based pricing framework "MARIE" for new clinical status.

Takami A, Sakashita N, Uenishi T, Shoji A, Igarashi A. Takami A, et al. J Med Econ. 2025 Dec;28(1):606-614. doi: 10.1080/13696998.2025.2492478. Epub 2025 Apr 30. J Med Econ. 2025. PMID: 40223437 Free article.

195

Artificial intelligence in key pricing, reimbursement, and market access (PRMA) processes: better, faster, cheaper-can you really pick two?

Dietrich ES. Dietrich ES. J Med Econ. 2025 Dec;28(1):586-595. doi: 10.1080/13696998.2025.2488154. Epub 2025 Apr 17. J Med Econ. 2025. PMID: 40167461 Free article.

196

Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adults.

de Courville C, Tadera C, Arashiro T, Bianic F, Costa M, Joshi M, Wang X. de Courville C, et al. J Med Econ. 2025 Dec;28(1):544-555. doi: 10.1080/13696998.2025.2488151. Epub 2025 Apr 8. J Med Econ. 2025. PMID: 40167444 Free article.

197

A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Lindgren SC, Strid H, Hjortswang H, Manxhuka B, Nanu N, Pollock RF. Lindgren SC, et al. J Med Econ. 2025 Dec;28(1):567-575. doi: 10.1080/13696998.2025.2487359. Epub 2025 Apr 15. J Med Econ. 2025. PMID: 40167340 Free article.

198

Healthcare resource utilization patterns among patients with Parkinson's disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine.

Rajagopalan K, Gopal D, Chrones L, Doshi D, Rashid N. Rajagopalan K, et al. J Med Econ. 2025 Dec;28(1):556-566. doi: 10.1080/13696998.2025.2487358. Epub 2025 Apr 30. J Med Econ. 2025. PMID: 40167335 Free article.

199

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.

Mahmoudjafari Z, Li J, Bercaw E, Parisé H, Bognar K, Wang ST, Masaquel A. Mahmoudjafari Z, et al. J Med Econ. 2025 Dec;28(1):595-604. doi: 10.1080/13696998.2025.2486839. Epub 2025 May 2. J Med Econ. 2025. PMID: 40163049 Free article.

200

All-cause healthcare resource utilization and costs among community-managed adults with long-COVID in France, 2020-2023.

Yang J, Tamberou C, Arnee E, Squara PA, Boukhlal A, Nguyen JL, Volkman HR, Fiévez S, Lepoutre-Bourguet M, Ren J, Ben Romdhane H, Crépey P, Robineau O. Yang J, et al. J Med Econ. 2025 Dec;28(1):535-543. doi: 10.1080/13696998.2025.2485626. Epub 2025 Apr 8. J Med Econ. 2025. PMID: 40162934 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,492 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,492 results

Results by year